Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373188 · ClinicalTrials.gov registry record · Phase 1
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03373188: Completed Phase 1 study, sponsored by Emory University.
NCT03373188 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373188, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
CD8+ T cells in tumor samples will be identified by immunohistochemistry and immunofluorescence staining, and we will quantitate the percentage and staining of the cells in the pancreatic and liver tissue with Integrated Cellular Imaging.
Interventions
- BIOLOGICAL Nivolumab
- PROCEDURE Surgery
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Anti-SEMA4D Monoclonal Antibody VX15/2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 1 |
What the finished NCT03373188 record still lists
NCT03373188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03373188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03373188 about?
NCT03373188 is a clinical study titled "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer". This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver...
What is the current status of trial NCT03373188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-12-15. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT03373188?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Surgery (PROCEDURE), Ipilimumab (BIOLOGICAL), Anti-SEMA4D Monoclonal Antibody VX15/2503 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03373188?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03373188's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI